Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report

Ann Intern Med. 2020 Oct 6;173(7):585-587. doi: 10.7326/L20-0549. Epub 2020 Aug 4.

Authors

Eugene Brailovski¹, Richard B Kim², David Juurlink¹

Affiliations

¹ University of Toronto, Toronto, Ontario, Canada (E.B., D.J.).
² University of Western Ontario, London, Ontario, Canada (R.B.K.).

PMID: 32744865
DOI: 10.7326/L20-0549

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Canagliflozin / adverse effects*
Canagliflozin / therapeutic use
Diabetes Mellitus, Type 2 / drug therapy
Drug Interactions
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
Myotoxicity / etiology*
Rosuvastatin Calcium / adverse effects*

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Canagliflozin
Rosuvastatin Calcium